Psychopharmacology and Psychiatry Updates

In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic territory — and if so, why?
Faculty: Paul Zarkowski, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 83
Can GLP-1 Agonists Elevate Lithium Levels?

In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safely, and why liver disease may not be the barrier you think it is. Can a medication that doesn't target abstinence still be a game-changer for your patients?
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder
Naltrexone for Alcohol Use Disorder: Dosing, Monitoring, and Liver Safety

In this episode, we explore the OPTIMUM trial, a landmark study examining how to treat older adults with treatment-resistant depression when antidepressants fall short. When adding a medication outperforms switching entirely — and what that means for the patient sitting across from you — the answer may reshape your clinical approach.
Faculty: Scott Beach, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 83
Antidepressant Augmentation vs. Switching in Geriatric Depression: Key Findings from the OPTIMUM Trial

In this episode, we explore what to do when antidepressants aren't working. How do you systematically approach a patient who isn't getting better — and when do you switch versus augment? Dr. Sagar Parikh walks through CANMAT's evidence-based framework for difficult-to-treat depression.
Faculty: Sagar V. Parikh, M.D., F.R.C.P.C.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CME: Rethinking Depression Treatment: An Update of CANMAT's Guidelines
Pharmacologic Management of Difficult-to-Treat Depression: First, Second, and Third Line Options

In this episode, we explore whether high-dose olanzapine — beyond the FDA-approved 20 mg ceiling — can be a viable strategy for patients with treatment-resistant schizophrenia when clozapine isn't yet an option. Can pushing the dose bridge the gap between partial response and full remission?
Faculty: Oliver Freudenreich, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CME: Quick Take Vol. 83
Treatment-Resistant Schizophrenia: Should You Consider High-Dose Olanzapine Instead of Clozapine?